Platelets and Plasma Lipids Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis
Development and Validation of a New Method to Valuate the Platelet-Plasma Lipid Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis
The objective of this clinical trial is to compare the effect of two different lipid emulsion formulations versus no emulsion on platelet aggregation in individuals without a history of ischemic disease. The hypothesis of this study is:
Platelet aggregation is inversely associated with higher plasma lipid concentrations.
The researchers will compare platelet aggregation in the presence and absence of lipid nanoemulsions in vitro through three pathways using the agonists collagen, adenosine diphosphate, and arachidonic acid. The tests will be performed using light-transmission aggregometry. Various participant parameters, such as lipid profile, will be evaluated to analyze possible correlations with the observed results.
Participants must:
Meet the study's inclusion criteria; Sign the informed consent form; Report to the blood draw laboratory at InCor's AB on the scheduled date and time after fasting for at least 8 hours.
研究概览
地位
条件
详细说明
A prospective case-control study in which the selected volunteers will serve as their own controls.
Participant Selection:
Volunteers with no known atherosclerotic disease will be selected from among employees of InCor/HCFMUSP and, if necessary, from the donor waiting list of the HCFMUSP blood bank.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:José C Nicolau, Senior Professor
- 电话号码:11971514117
- 邮箱:jose.nicolau@fm.hc.usp.br
研究联系人备份
- 姓名:Juliana L L F Regueira, Postdoctoral Res. Associate
- 电话号码:11959564983
- 邮箱:julianaliraregueira@gmail.com
学习地点
-
-
São Paulo
-
São Paulo、São Paulo、巴西、05403-900
- 招聘中
- Heart Institute, University of São Paulo Medical School (InCor/HCFMUSP)
-
副研究员:
- Juliana L. L. F. Regueira, PhD
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Men and women aged ≥ 40 years.
- Willingness to sign the informed consent form.
- Absence of known atherosclerotic disease
Exclusion Criteria:
- Use of antiplatelet agents.
- Use of anticoagulants.
- Use of lipid-lowering agents.
- Use of oral hypoglycemic agents or insulin.
- Known atherosclerotic disease.
- Refusal to sign the informed consent form
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Control group
The same group of study participants.
Platelet aggregation tests without the addition of lipid nanoemulsions.
|
|
Case group
Study participants.
Platelet aggregation tests with the addition of lipid nanoemulsions.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Effect of Lipid Emulsions on Platelet Aggregation Assessed by Optical Aggregometry
大体时间:Day 1 (single blood sample collection)
|
Comparison of the effect of different lipid emulsion formulations versus no emulsion (control) on platelet aggregation in blood samples from individuals without a history of ischemic disease.
|
Day 1 (single blood sample collection)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- SDC: 6137/25/148
- 2023/10447-4 (其他赠款/资助编号:Fapesp)
- 2025/29035-3 (其他赠款/资助编号:Fapesp)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享支持信息类型
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.